Documents in the NTIS Technical Reports collection are the results of federally funded research. They are directly submitted to or collected by NTIS from Federal agencies for permanent accessibility to industry, academia and the public.  Before purchasing from NTIS, you may want to check for free access from (1) the issuing organization's website; (2) the U.S. Government Printing Office's Federal Digital System website http://www.gpo.gov/fdsys; (3) the federal government Internet portal USA.gov; or (4) a web search conducted using a commercial search engine such as http://www.google.com.
Accession Number ADA575594
Title Targeting Chemerin Receptor CMKLR1 in Multiple Sclerosis.
Publication Date Sep 2012
Media Count 69p
Personal Author B. Zabel
Abstract Therapies that target leukocyte trafficking pathways can reduce disease activity and improve clinical outcomes in multiple sclerosis (MS). Experimental autoimmune encephalomyelitis (EAE) is a widely studied animal model that shares many clinical and histological features with human MS. Chemokine-like receptor-1 (CMKLR1) is a chemoattractant receptor that is expressed by key effector cells in EAE and MS, including macrophages, subsets of dendritic cells, natural killer cells and microglia. CMKLR1-deficient mice develop less severe clinical and histological EAE than wild-type mice. In this study, we identified alphanaphthoyl ethyltrimethylammonium iodide (alpha-NETA) as a selective CMKLR1 small molecule antagonist that inhibits chemerin- triggered CMKLR1+ cell migration. Prophylactic dosing with alpha-NETA significantly delayed the onset of EAE induced in C57BL/6 mice. In addition, alpha-NETA treatment significantly inhibited accumulation of inflammatory leukocytes within the CNS. This study provides additional proof-of-concept data that targeting CMKLR1:chemerin interactions may be beneficial in preventing or treating MS.
Keywords Autoimmunization
Cells
Central nervous system
Chemerin
Clinical medicine
Cmklr1(Chemokine-like receptor-1)
Diseases
Experimental autoimmune encephalomyelitis
Histology
Leukocytes
Migration
Ms(Multiple sclerosis)
Preventive medicine
Receptor sites(Physiology)
Sense organs
Targeting
Therapy


 
Source Agency Non Paid ADAS
NTIS Subject Category 57A - Anatomy
57S - Physiology
57E - Clinical Medicine
Corporate Author Palo Alto Inst. for Research and Education, Inc., CA.
Document Type Technical report
Title Note Annual rept. 29 Aug 2011-28 Aug 2012.
NTIS Issue Number 1319
Contract Number W81XWH-11-1-0512

Science and Technology Highlights

See a sampling of the latest scientific, technical and engineering information from NTIS in the NTIS Technical Reports Newsletter

Acrobat Reader Mobile    Acrobat Reader